Evolution of HER2 expression between pre-treatment biopsy and residual disease after neoadjuvant therapy for breast cancer

We have previously found that HER2 expression is dynamic, and can change from the primary breast tumor to matched recurrences. With this work, we aimed to assess the dynamics of HER2 during neoadjuvant treatment.(NAT).

Source: European Journal of Cancer - February 10, 2024 Category: Cancer & Oncology Authors: Paolo Tarantino, Ogheneochuko Ajari, Noah Graham, Julie Vincuilla, Tonia Parker, Melissa E. Hughes, Nabihah Tayob, Ana C. Garrido-Castro, Stefania Morganti, Tari A. King, Elizabeth A. Mittendorf, Giuseppe Curigliano, Nancy U. Lin, Sara M. Tolaney Tags: Original research Source Type: research